

CIRM Funded Clinical Trials

## Progenitor Cells Secreting GDNF for the Treatment of ALS

<b>Disease Area:</b>	Amyotrophic Lateral Sclerosis
<b>Investigator:</b>	Clive Svendsen
<b>Institution:</b>	Cedars-Sinai Medical Center
<b>CIRM Grant:</b>	CLIN2-09284
<b>Award Value:</b>	\$6,154,067
<b>Trial Sponsor:</b>	Cedars-Sinai Medical Center
<b>Trial Stage:</b>	Phase 1/2
<b>Trial Status:</b>	Completed
<b>Targeted Enrollment:</b>	18
<b>ClinicalTrials.gov ID:</b>	NCT02943850



Clive Svendsen

**Details:**

ALS is a devastating neurodegenerative disease with no cure that specifically affect a patient's motor neurons in the brain. A team at Cedars-Sinai is transplanting millions of genetically engineered stem cells into patients with ALS. When transplanted into the patient spinal cord, these cells become astrocytes, the support cells that keep nerve cells functioning. Due to the genetic modifications, the cells also deliver high doses of a growth factor which has been shown to protect nerve cells. The goal of this early stage trial is to test the safety of this astrocyte replacement strategy in ALS patients.

**Design:**

Dose escalation. Open label.

**Goal:**

Safety. Dosing. Efficacy - Lower limb strength

**News about this clinical trial:**

CIRM-Funded Clinical Trial for ALS Given Go Ahead to Treat Patients

Cedars-Sinai Receives Approval to Test Novel Combined Stem Cell and Gene Therapy for ALS Patients

Contact Trial Sponsor